Immunosuppression in two cases of indeterminate hepatitis.

Can Liver J

Department of Pediatrics, Université de Montréal, CHU Sainte-Justine, Montréal, Quebec, Canada.

Published: February 2024

Background: Pediatric acute liver failure (PALF) is a potentially lethal and rapidly progressive clinical syndrome, with a large proportion of cases remaining indeterminate despite extensive investigations.

Patients And Results: In this case report, we describe two male children with indeterminate PALF and a family history of autoimmune disease, both of whom were lymphopenic with necrosis, inflammation, and lymphocytic infiltrates on their liver biopsies. One of these patients subsequently developed hepatitis-associated aplastic anemia. Notably, in addition to receiving standard liver failure care, both patients were successfully treated off-label with anti-thymocyte globulin (ATG), as well as a more prolonged course of cyclosporine and corticosteroids.

Conclusions: The fact that these medications all suppress T lymphocytes further supports the theory that T-cell activation plays a prominent role in the pathophysiology of indeterminate hepatitis. Further research should examine the short-term and long-term effects of ATG in this population, as well as the necessary duration of treatment with immune-suppressing agents.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10946185PMC
http://dx.doi.org/10.3138/canlivj-2023-0019DOI Listing

Publication Analysis

Top Keywords

indeterminate hepatitis
8
liver failure
8
immunosuppression cases
4
indeterminate
4
cases indeterminate
4
hepatitis background
4
background pediatric
4
pediatric acute
4
acute liver
4
failure palf
4

Similar Publications

Epidemiological insights into severe hepatitis in pediatric inpatients.

iScience

December 2024

Department of Information Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China.

There is limited statistical data on severe hepatitis among hospitalized children in China at a national level. This nationwide study analyzed data from 34,410 children hospitalized for severe hepatitis in mainland China from 2016 to 2022. The overall in-hospital mortality rate was 6.

View Article and Find Full Text PDF

Real-world data on treatment outcomes or the quality of large-scale chronic hepatitis B (CHB) treatment programs in sub-Saharan Africa (SSA) is extremely difficult to obtain. In this study, we aimed to provide data on the prevalence and incidence of mortality, loss to follow-up (LFTU), and their associated factors in patients with CHB in three treatment centres in Eritrea. Additional information includes baseline clinical profiles of CHB patients initiated on nucleos(t)ide analogue (NUCs) along with a comparison of treatment with Tenofovir disoproxil fumarate (TDF) vs.

View Article and Find Full Text PDF

Definitions, etiopathogenesis and epidemiology of ALF.

Best Pract Res Clin Gastroenterol

December 2024

Department of Gastroenterology and Human Nutrition Unit, All India Institute of Medical Sciences, New Delhi, India. Electronic address:

Acute liver failure (ALF) is a rare but preventable cause of acute hepatic dysfunction which is associated with significant mortality, unless treated appropriately. There are significant regional variations in the etiologies of ALF globally and this determines the outcomes of the disease as well as the long-term survival in patients receiving liver transplantation for management. Improvements in understanding of disease pathophysiology and critical care medicine have led to better outcomes over the last few decades.

View Article and Find Full Text PDF
Article Synopsis
  • HCV guidelines suggest using direct-acting antivirals (DAA) for patients who either fail treatment or get reinfected, but identifying the cause of HCV viremia in patients with follow-up issues is tricky.
  • A study analyzed the outcomes of 112 patients in Massachusetts who were retreated with either first-line or rescue DAA therapies after having indeterminate prior treatment outcomes.
  • Results indicated that first-line DAA therapy had similar effectiveness to rescue therapy, showing comparable rates of sustained virologic response and treatment failure, suggesting potential for easing treatment access for HCV patients.
View Article and Find Full Text PDF

Background And Aims: In chronic hepatitis B (CHB), an indeterminate phase exists outside the typical predefined phases. Our study investigates this indeterminate phase's natural history and prognosis, focusing on antiviral treatment outcomes.

Methods: We conducted a retrospective cohort study to compare the risk of transitioning to immune active phase between inactive and indeterminate CHB and the incidence of hepatocellular carcinoma (HCC) and cirrhosis between untreated patients with indeterminate CHB (at baseline and throughout follow-up) and those who received treatment, following standard AASLD 2018 guidance.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!